Capricor Therapeutics, Inc. (Nasdaq:CAPR) is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapeutics for the treatment of cardiac and other serious medical conditions. Our innovative technology builds upon a large body of scientific research and enables us to approach the treatment of diseases in novel ways.
Capricor’s lead candidate, CAP-1002, is an “off-the-shelf” cardiac cell therapy that is currently in clinical development for the treatment of heart disease associated with Duchenne muscular dystrophy (DMD) as well as adult cardiology conditions. The power of Capricor’s technology to address heart disease was first demonstrated clinically in the randomized CADUCEUS clinical trial, which showed, following a single administration, significant reductions in the size of the scar that had resulted from a large heart attack, as well as significant increases in muscle mass at the affected area.
We have been collaborating on the manufacturing of CAP-1002 with Janssen Biotech, Inc. which holds an option to license this candidate for certain cardiology indications.
Capricor has also established itself as one of the leading companies investigating the field of exosome science. Exosomes are nanosized particles with biologically-active contents that are secreted by cells and serve to direct or re-direct the activities of other cells and are emerging as an exciting class of potential therapeutic agents. Our studies have been showing that our exosome technology is significantly active in several disease models. We are initially advancing CAP-2003, our proprietary exosome product candidate, for the treatment of ocular graft-versus-host disease.